DRUG SAFETY AND POLYMORBIDITY AS IMPORTANT COMPONENTS OF RATIONAL PHARMACOTHERAPY IN CARDIOLOGY


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

In modern conditions, the appointment of rational pharmacotherapy for patients is far from being the easiest task. Lifestyle changes, as well as a gradual increase in life expectancy of the population, have led to the fact that the previously existing approach «one patient - one disease» is outdated and cannot be used in clinical practice. In this regard, the selection of an effective and at the same time safe drug therapy for such patients with several diseases at the same time requires a doctor to have a wide range of knowledge both in terms of pathophysiology and clinical pharmacology, in particular, knowledge of drug safety and organoprotective properties of medicines is of particular importance. The proposed article highlights the issues of effective and safe pharmacotherapy in comorbid patients with an emphasis on cardiovascular diseases. It also presents a clinical case that discusses the rational pharmacotherapy of arterial hypertension, namely the use of the thiazide-like diuretic indapamide as part of combination therapy, in a patient with obesity and dyslipidemia.

Full Text

Restricted Access

About the authors

Olga A. Polyakova

Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of Russia

Email: docpolyakova.olga@gmail.com
therapist, assistant at the Department of therapy and polymorbid pathology named after academician M.S. Vovsi 125993, Moscow, 2/1 bulding 1 Barrikadnaya Str

Olga D. Ostroumova

Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of Russia

Email: ostroumova.olga@mail.ru
Dr. med. habil., professor, head of the Department of therapy and polymorbid pathology named after academician M.S. Vovsi 125993, Moscow, 2/1 bulding 1 Barrikadnaya Str

Alexander V. Arablinsky

Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of Russia; S.P. Botkin City Clinical Hospital of the Moscow Department of Healthcare

Dr. med. habil., professor of the Department of therapy and polymorbid pathology named after academician M.S. Vovsi; head of the Department of X-ray surgical methods of diagnosis and treatment 125993, Moscow, 2/1 bulding 1 Barrikadnaya Str

References

  1. Лекарственно-индуцированные заболевания. Том III: монография. Под общ. ред. Д.А. Сычева, О.Д. Остроумовой; ред. раздела А.И. Кочетков. М.: Прометей, 2022; 566 с. ISBN: 978-5-00172-329-5
  2. Рекомендации по рациональной фармакотерапии больных сердечно-сосудистыми заболеваниями. Кардиоваскулярная терапия и профилактика. 2009; 6S4: 2-56. https://dx.doi.org/10.15829/1728-8800-2009-6S4-2-56
  3. Оганов Р.Г., Симаненков В.И., Бакулин И.Г. с соавт. Коморбидная патология в клинической практике. Алгоритмы диагностики и лечения. Кардиоваскулярная терапия и профилактика. 2019; 1: 5-66. https://dx.doi.org/10.15829/1728-8800-2019-1-5-66
  4. Alshammari T.M. Drug safety: The concept, inception and its importance in patients' health. Saudi Pharm J. 2016; 24(4): 405-12. https://dx.doi.org/10.1016/j.jsps.2014.04.008.
  5. Geiling E.M.K., Cannon P.R. Pathologic effects of elixir of sulfanilamide (diethylene glycol) poisoning: a clinical and experimental correlation. Journal of the American Medical Association. 1938; 111(10): 919-26.
  6. Wax P.M. Elixirs, diluents, and the passage of the 1938 Federal Food, Drug and Cosmetic Act. Ann Intern Med. 1995; 122(6): 456-61. https://dx.doi.org/10.7326/0003-4819-122-6-199503150-00009.
  7. Лукина Ю.В., Дмитриева Н.А., Кутишенко Н.П. с соавт. Взаимосвязь и взаимовлияние аспектов безопасности лекарственного лечения и приверженности терапии у больных сердечно-сосудистыми заболеваниями (по данным амбулаторного регистра «ПРОФИЛЬ»). Кардиоваскулярная терапия и профилактика. 2018; 5: 72-78. https://dx.doi.org/10.15829/1728-8800-2018-5-72-78.
  8. Hilmer S.N., McLachlan A.J., Le Couteur D.G. Clinical pharmacology in the geriatric patient. Fundam Clin Pharmacol. 2007; 21(3): 217-30. https://dx.doi.org/10.1111/j.1472-8206.2007.00473.x.
  9. Bunchorntavakul C., Reddy K.R. Acetaminophen-related hepatotoxicity. Clin Liver Dis. 2013; 17(4): 587-607. https://dx.doi.org/10.1016/j.cld.2013.07.005.
  10. Tamargo J., Kjeldsen K.P., Delpon E. et al. Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. Eur Heart J Cardiovasc Pharmacother. 2022; pvac005. https://dx.doi.org/10.1093/ehjcvp/pvac005. Online ahead of print.
  11. Franconi F., Brunelleschi S., Steardo L., Cuomo V. Gender differences in drug responses. Pharmacol Res. 2007; 55(2): 81-95. https://dx.doi.org/10.1016/j.phrs.2006.11.001.
  12. Damluji A.A., Forman D.E., van Diepen S. et al. Older adults in the cardiac intensive care unit: Factoring geriatric syndromes in the management, prognosis, and process of care: A scientific statement from the American Heart Association. Circulation. 2020; 141(2): 147 e6-e32. https://dx.doi.org/10.1161/CIR.0000000000000741.
  13. Paneni F., Diaz Canestro C., Libby P. et al. The aging cardiovascular system: understanding it at the cellular and clinical levels. J Am Coll Cardiol. 2017; 69(15): 1952-67. https://dx.doi.org/10.1016/j.jacc.2017.01.064.
  14. Трухан Д.И. Рациональная фармакотерапия в реальной клинической практике сквозь призму мультиморбидности и лекарственной безопасности. Клинический разбор в общей медицине. 2020; 2: 29-39. https://dx.doi.org/10.47407/kr2020.1.2.00015.
  15. Violan C., Foguet-Boreu Q., Flores-Mateo G. et al. Prevalence, determinants and patterns of multimorbidity in primary care: A systematic review of observational studies. PLoS One. 2014; 9(7): 1-9. https://dx.doi.org/10.1371/journal.pone.0102149.
  16. Qato D.M., Wilder J., Schumm L.P. et al. Changes in prescription and over-the-counter medication and dietary supplement use among older adults in the United States, 2005 vs 2011. JAMA Intern Med. 2016; 176(4): 473-82. https://dx.doi.org/10.1001/jamainternmed.2015.8581.
  17. Schwartz J.B., Schmader K.E., Hanlon J.T. et al. Pharmacotherapy in older adults with cardiovascular disease: Report from an American College of Cardiology, American Geriatrics Society, and National Institute on Aging Workshop. J Am Geriatr Soc. 2019; 67(2): 371-80. https://dx.doi.org/10.1111/jgs.15634.
  18. Dunlay S.M., Chamberlain A.M. Multimorbidity in older patients with cardiovascular disease. Curr Cardiovasc Risk Rep. 2016; 10: 3. https://dx.doi.org/10.1007/s12170-016-0491-8.
  19. Rich M.W., Chyun D.A., Skolnick A.H. et al. Knowledge gaps in cardiovascular care of older adults: A scientific statement from the American Heart Association, American College of Cardiology, and American Geriatrics Society: Executive summary. J Am Geriatr Soc. 2016; 64(11): 2185-92. https://dx.doi.org/10.1111/jgs.14576.
  20. Zamorano J.L., Lancellotti P., Rodriguez Munoz D. et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016; 37(36): 2768-801. https://dx.doi.org/10.1093/eurheartj/ehw211.
  21. Hovstadius B., Astrand B., Petersson G. Dispensed drugs and multiple medications in the Swedish population: An individual-based register study. BMC Clin Pharmacol. 2009; 9: 11. https://dx.doi.org/10.1186/1472-6904-9-11.
  22. Баланова Ю.А., Шальнова С.А., Деев А.Д. и др. Ожирение в российской популяции - распространенность и ассоциации с факторами риска хронических неинфекционных заболеваний. Российский кардиологический журнал. 2018; 6: 123-130. https://dx.doi.org/10.15829/1560-4071-2018-6-123-130.
  23. Derington C.G., Gums T.H., Bress A.P. et al. Association of total medication burden with intensive and standard blood pressure control and clinical outcomes: A secondary analysis of SPRINT. Hypertension. 2019; HYPERTENSIONAHA11912907. https://dx.doi.org/10.1161/HYPERTENSIONAHA.119.12907. Online ahead of print.
  24. Laslett L.J., Alagona P. Jr, Clark B.A. 3rd et al. The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy and policy issues: a report from the American College of Cardiology. J Am Coll Cardiol. 2012; 60(25 Suppl): S1-S49. https://dx.doi.org/10.1016/j.jacc.2012.11.002.
  25. Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020; 3: 149218. https://dx.doi.org/10.15829/1560-4071-2020-3-3786.
  26. Деев А.Д., Марцевич С.Ю., Кутишенко Н.П. с соавт. Изучение эффективности и переносимости препарата ИНДАПвсравнении с препаратами АРИФОН и АРИФОН ретард у больных мягкой и умеренной артериальной гипертонией, назначаемых как в виде монотерапии, так и в комбинации с ингибиторами АПФ. Многоцентровое, открытое, рандомизированное перекрестное исследование. Российский кардиологический журнал. 2006; 2: 73-77
  27. Деев А.Д., Марцевич С.Ю., Бобкова Л.П. с соавт. Терапия артериальной гипертонии I и II степени. Оценка терапевтической эквивалентности генерика индапамида в сравнении с обычной и ретардированной формой оригинального препарата. Справочник поликлинического врача. 2006; 5: 33-37
  28. Кутишенко Н.П., Якусевич В.В., Деев А.Д. с соавт. Оценка терапевтической эквивалентности оригинального индапамида и индапамида-дженерика у больных артериальной гипертонией с помощью рандомизированного перекрестного исследования. Рациональная фармакотерапия в кардиологии. 2007;2: 26-30
  29. Ostroumova O.D., Polyakova O.A., Listratova A.I. et al. Thiazide and thiazide-like diuretics: how to make the right choice? Kardiologiia. 2022; 62(1): 89-97. https://dx.doi.org/10.18087/cardio.2022.1.n1862.
  30. Marre M., Puig J.G., Kokot F. et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study. J Hypertens. 2004; 22(8): 1613-22. https://dx.doi.org/10.1097/01.hjh.0000133733.32125.09.
  31. Musini V.M., Nazer M., Bassett K. et al. Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension. Cochrane Database Syst Rev. 2014; 5: 1-185. https://dx.doi.org/10.1002/14651858.CD003824.pub2.
  32. Senior R., Imbs J.L., Bory M. et al. Indapamide reduces hypertensive left ventricular hypertrophy: an international multicenter study. J Cardiovasc Pharmacol. 1993; 22 Suppl 6: S106-S110.
  33. Roush G.C., Abdelfattah R., Song S. et al. Hydrochlorothiazide and alternative diuretics versus renin-angiotensin system inhibitors for the regression of left ventricular hypertrophy: a head-to-head meta-analysis. J Hypertens. 2018; 36(6): 1247-55. https://dx.doi.org/10.1097/HJH.0000000000001691.
  34. Tzourio C., Anderson C., Chapman N. et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med. 2003; 163(9): 1069-75. https://dx.doi.org/10.1001/archinte. 163.9.1069.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2022 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies